Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of aflibercept plus LV5FU2 as first-line treatment for unresectable metastatic colorectal cancer in older adults
2014-001837-10Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2015
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aflibercept, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Proportion alive and without progression at 6 months. Started Jan 2015; status: completed.
02
Drugs
afliberceptfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-001837-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001837-10.